Skip to main content
OpenTrials
Completed

NCT Number: NCT02093065

Platelet Function in Patients With Hemophilia A

Abnormalities in the gene encoding Factor VIII (FVIII) results in hemophilia A, an X-linked recessive bleeding disorder with a prevalence of 1 in 5000 males. Hemophilia A patients are classified into 3 different categories based on residual FVIII activity compared to normal: mild (6-40%), moderate (1-5%) and severe (<1%). This categorization correlates to some degree with bleeding phenotype, but does not completely define it. Some patients with hemophilia A bleed less often than others despite identical plasma FVIII levels. The cause(s) of this phenotype heterogeneity in hemophilia A remains largely unknown, despite a number of studies of possible factors.

Activated platelets, in addition to their role in primary hemostasis, play a major role in secondary hemostasis (coagulation) by providing a phospholipid surface to which coagulation factors bind. A role for platelets in the hemorrhagic propensity of hemophilia A has been suggested in the past, but only a small number of studies have been performed with limitations in assays performed and numbers of patients. The purpose of the present study is to determine whether platelet reactivity in severe hemophilia A patients is associated with past bleeding frequency and/or predicts future bleeding frequency.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with severe hemophilia A who are being prophylactically treated with FVIII.
  • Age of at least 2 years.
  • Bleeding history of at least 6 months.
  • IRB-approved informed consent.

Exclusion criteria

  • Presence of FVIII inhibitors.
  • Greater than 7 days since active bleeding.

Treatment and study plan

Primary outcomes

  1. The percentage of coated platelets.

    Time frame: 2 years

Secondary outcomes

  1. Platelet reactivity.

    Time frame: 2 years

  2. The number of procoagulant platelet-derived microparticles.

    Time frame: 2 years

Sponsors and collaborators

Lead sponsor

Boston Children's Hospital

Other

Collaborators

  • Baxter Healthcare Corporation

Registry information

Official study title

Decreased Platelet Function as a Cause of Increased Bleeding in Patients With Hemophilia A

Important dates

Study start
2015
Primary completion
2018
Study completion
2020
First posted
Mar 20, 2014
Registry last updated
Jul 14, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.